Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters
Open Access
- 18 November 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Abstract
Chimeric antigen receptor T (CAR-T) cells show remarkable efficacy for some hematological malignancies. However, CAR targets that are expressed at high level and selective to tumors are scarce. Several strategies have been proposed to tackle the on-target off-tumor toxicity of CAR-T cells that arise from suboptimal selectivity, but these are complicated, with many involving dual gene expression for specificity. In this study, we show that switchable CAR-T cells with a tumor targeting adaptor can mitigate on-target off-tumor toxicity against a low selectivity tumor antigen that cannot be targeted by conventional CAR-T cells, such as CD40. Our system is composed of anti-cotinine murine CAR-T cells and cotinine-labeled anti-CD40 single chain variable fragments (scFv), with which we show selective tumor killing while sparing CD40-expressing normal cells including macrophages in a mouse model of lymphoma. Simple replacement of the tumor-targeting adaptor with a suicidal drug-conjugated tag may further enhance safety by enabling permanent in vivo depletion of the switchable CAR-T cells when necessary. In summary, our switchable CAR system can control CAR-T cell toxicity while maintaining therapeutic efficacy, thereby expanding the range of CAR targets.Keywords
Funding Information
- Korea Drug Development Fund (HN21C0764)
- National Research Foundation of Korea (RS-2023-00260454, 2016M3A9D3900438)
This publication has 74 references indexed in Scilit:
- Enhanced safety and efficacy of protease-regulated CAR-T cell receptorsCell, 2022
- Engineering CAR-T Cells for Next-Generation Cancer TherapyCancer Cell, 2020
- Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor TargetingCancer Cell, 2019
- CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor ResponseCancer Cell, 2019
- A Hybrid Platform Based on a Bispecific Peptide–Antibody Complex for Targeted Cancer TherapyAngewandte Chemie International Edition, 2019
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell ResponsesCell, 2018
- The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicityCancer Immunology, Immunotherapy, 2017
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing CircuitsCell, 2016
- A sensitive enzyme immunoassay for measuring cotinine in passive smokersClinica Chimica Acta, 2010
- Pulmonary endothelium in acute lung injury: from basic science to the critically illIntensive Care Medicine, 2004